【作者】 徐慧婷； 臧爱华； 张海琳； 冉凤鸣； 王志军； 于丁；

【Author】 XU Hui-ting~1,ZANG Ai-hua~1,ZHANG Hai-ling~2,RAN Feng-ming~1,WANG Zhi-jun~1,YU Ding~1 1.Department of Medical oncology,Hubei Cancer Hospital,Wuhan 430079,China;2. Zhijiang people’s hospital,Zhijiang 443200

【机构】 湖北省肿瘤医院内科武汉； 枝江市人民医院肿瘤科；

【摘要】 目的观察抗肿瘤新药重组人血管内皮抑素注射液联合化疗对比单纯化疗治疗晚期NSCLC的有效性和安全性。方法经组织学或细胞学确诊的Ⅲb～Ⅳ期NSCLC患者104例,分为2组。试验组41例接受重组人血管内皮抑素加常规化疗药物联合治疗,对照组63例接受单纯常规化疗。按照RECIST标准评价近期客观疗效,按照NCI CTC 3.0版的分级标准评价药物毒性。治疗2周期后评价毒性和疗效。结果所有104例患者均可评价疗效。试验组和对照组的总临床有效率(RR)分别为34.15%和30.16%,实验组较对照组高,总临床获益率(CBR)分别为73.17%和71.43%;初治患者RR分别为34.78%和39.02%,CBR分别为73.91%和80.49%;复治患者RR分别为33.33%和13.64%,CBR分别为72.22%和54.55%;疗效与病理类型有关,腺癌比鳞癌效果好,在同一病理类型中试验组与对照组疗效相似,鳞癌患者RR分别为27.27%和28.00%,CBR分别为81.82%和72.00%;腺癌患者RR分别为36.67%和31.58%,CBR分别为70.00%和71.05%。试验组与对照组患者生活质量在症状、Karnofsky评分、体重三方面均无统计学差异(P>0.05)。试验组与对照组均未出现严重不良反应,Ⅲ～Ⅳ°不良反应发生率无显著性差异(P>0.05)。结论重组人血管内皮抑素联合化疗治疗晚期NSCLC耐受性好,可以提高化疗的有效率,用于复治时疗效提高更为显著。更多还原

【Abstract】 Objective To investigate and compare the short-term effect and safety of rh-endostatin(endostar) combined chemotherapy and conventional chemotherapy for NSCLC.Methods There were 104 patients with advanced non-small cell lung cancer confirmed by histopathology or cytopathology,divided into two groups,41 patients were given rh-endostatin plus chemotherapy(trial group),and 63 patients were given chemotherapy only(control group).The efficacy and toxicity were evaluated after 2 cycles according to RECIST criteria and NCI CTC 3.0 respectively.Results Totally, 104 patients were entered and all of these patients were evaluable.The total response rate(RR) in two groups were 34.15%and 30.16%,total clinical benefit rate (CBR) were 73.17%and 71.43%.The RR of untreated patients were 34.78%and 39.02%, CBR were 73.91%and 80.49%.The RR of retreated patients were 33.33%and 13.64%, CBR were 72.22%and 54.55%.The RR of squamous cell carcinoma were 27.27%and 28.00%, CBR were 81.82%and 72.00%.The RR of adenocarcinoma were 36.67%and 31.58%,CBR were 70.00%and 71.05%.There was no significant difference in patients’ quality of life in two groups,and the incidence rates of side effect showed no statistical difference between two groups(P>0.05).Conclusion The chemotherapy combined with rh-endostatin tended to show a better efficacy than chemotherapy alone and was well-tolerated in patients with non-small cell lung cancer,especially for the retreated patients..更多还原